TWiV 758: COVID-19 clinical update #63 with Dr. Daniel Griffin

<p>In COVID-19 clinical update #63, Daniel Griffin reviews cases at child care facilities, estimates of mRNA vaccine effectiveness, risk of reinfection in university students, enhanced antibody generation with extended interval of mRNA vaccination, no benefit of convalescent plasma in hospitalized patients, and risk of clinical sequelae after acute infection.</p> <p>Hosts: <a href="http://parasiteswithoutborders.com/">Daniel Griffin</a> and <a href= "http://en.wikipedia.org/wiki/Vincent_Racaniello">Vincent Racaniello</a></p> <p>Subscribe (free): <a href= "http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?id=300973784">iTunes</a>, <a href="https://www.google.com/podcasts?feed=aHR0cDovL3R3aXYubWljcm9iZXdvcmxkLmxpYnN5bnByby5jb20vdHdpdg%3D%3D">Google Podcasts</a>, <a href= "http://twiv.microbeworld.libsynpro.com/twiv">RSS</a>, <a href="http://eepurl.com/Gcw59">email</a></p> <p>Become a <a href= "https://www.microbe.tv/contribute">patron</a> of TWiV!</p> <h3><strong>Links for this episode</strong></h3> <ul> <li>COVID-19 in <a href= "https://www.cdc.gov/mmwr/volumes/70/wr/mm7020a3.htm?s_cid=mm7020a3_w"> child care facilities</a> (MMWR)</li> <li>mRNA vaccine <a href= "https://www.cdc.gov/mmwr/volumes/70/wr/mm7020e2.htm">effectiveness</a> (MMWR)</li> <li><a href= "https://covid19vaccine.health.ny.gov/excelsior-pass">Excelsior pass</a> (NYS)</li> <li>Risk of SARS-CoV-2 <a href= "https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab454/6276528"> reinfection</a> in university students (CID)</li> <li>Enhanced antibody production with <a href= "https://www.medrxiv.org/content/10.1101/2021.05.15.21257017v1">longer mRNA vaccine interval</a> (medRxiv)</li> <li>Convalescent plasma trial in <a href= "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00897-7/fulltext"> hospitalized patients</a> (Lancet)</li> <li>Phase 3 data on <a href= "https://www.prnewswire.com/news-releases/phase-3-data-presented-at-ats-2021-show-regen-cov-casirivimab-with-imdevimab-reduced-risk-of-hospitalization-or-dea